Biomarkers in Barrett's esophagus

Area of Science:

• Gastroenterology and Molecular Diagnostics
• Biomarker Discovery and Validation

Background:

• Current risk stratification for Barrett's esophagus (BE) relies heavily on dysplasia grade, which has limitations.
• Existing studies show poor reproducibility and predictive value for dysplasia interpretation, hindering national surveillance guidelines.
• Over 60 biomarkers have been proposed, but few have advanced to late-stage clinical validation relevant for gastroenterologists.

Purpose of the Study:

• To provide a framework for interpreting Barrett's biomarker literature to improve patient care.
• To highlight the limitations of current dysplasia grading and the need for validated biomarkers.
• To discuss the progress and clinical utility of emerging biomarkers in BE management.

Main Methods:

• Review of published literature focusing on phase 3 and 4 studies of Barrett's esophagus biomarkers.
• Evaluation of the clinical relevance and validation status of various biomarkers, including flow cytometry and molecular markers.
• Assessment of the reproducibility and predictive value of dysplasia grading versus novel biomarkers.

Main Results:

• Flow cytometric analysis of tetraploidy and aneuploidy shows significant progress in validation and utility.
• Flow cytometry can identify patients at increased risk of cancer progression not detected by dysplasia grade alone.
• 17p (p53) loss of heterozygosity (LOH) is a promising molecular biomarker but not yet recommended for routine clinical use.

Conclusions:

• Dysplasia classification remains valuable but requires complementary biomarkers due to its inherent limitations.
• Validated biomarkers, such as flow cytometry, are crucial for improving risk stratification and surveillance in Barrett's esophagus.
• Continued research and multi-institutional collaborations are essential for advancing biomarker evaluation and clinical application in BE.